West Nile virus subtype Kunjin (KUNV)

Kunjin virus (KUNV) is a zoonotic flavivirus and a subtype of the West Nile virus (WNV) that is primarily endemic to Australia and parts of Southeast Asia (1.2.1, 1.2.4). While it is genetically and antigenically similar to the highly pathogenic North American WNV strains, KUNV is generally associated with milder clinical presentations, such as West Nile fever, though it can occasionally cause severe encephalitis (1.2.2, 1.3.3). The viral genome is a single-stranded, positive-sense RNA that encodes a polyprotein subsequently processed into three structural proteins and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) (1.1.2, 1.2.1). These non-structural proteins, particularly the NS3 protease and NS5 RNA-dependent RNA polymerase, serve as the primary molecular targets for antiviral drug development (1.3.2, 1.3.4). Currently, there are no FDA-approved vaccines or specific antiviral therapies for Kunjin virus infection, and clinical management is predominantly supportive (1.2.4). Research has explored the use of broad-spectrum antivirals like ribavirin and interferon-alpha, as well as experimental small molecules such as NITD-008, which targets the viral polymerase (1.3.2, 1.3.3). Additionally, Kunjin virus replicons have been investigated as potential vectors for gene therapy and vaccine delivery due to their non-cytopathic nature (1.3.1). The development of effective therapeutics is challenged by the virus's ability to evade the host immune response and the potential for neuroinvasive complications (1.1.1, 1.3.3).

Other names

Kunjin virusWNV-KUNWest Nile virus Kunjin subtypeWNV/KUN

Inhibition of viral RNA-dependent RNA polymerase (NS5) and NS2B-NS3 protease activity